The report provides a detailed analysis essential for establishing a Bumetanide production plant. It encompasses all critical aspects necessary for Bumetanide production, including the cost of Bumetanide production, Bumetanide plant cost, Bumetanide production costs, and the overall Bumetanide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Bumetanide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Bumetanide is a sulfamyl diuretic that is used to treat nephrotic syndrome, liver and renal disease, and edema associated with congestive heart failure. Its physiological action is to increase the diuresis at the loop of Henle; thus, it belongs to the category of loop diuretic. The medication can also be used off-label to treat acute hypercalcemia.
The procurement of Bumetanide is influenced by its application in the pharmaceutical and medical industries as a diuretic. The demand for Bumetanide is also increasing due to the rising cases of heart failure, liver cirrhosis, and chronic kidney disease. It witnesses a significant demand from the aging population as they are more likely to be affected by conditions such as heart and renal diseases. Additionally, refractory edema that is resistant to other loop diuretics may benefit from it, thus increasing its demand.
It may be used alone or with other antihypertensive medications in treating hypertension. Bumetanide may be a viable choice for people who have an adverse reaction to furosemide, another loop diuretic. The medication can also be used off-label to treat acute hypercalcemia. In general, industrial Bumetanide procurement is influenced by its application in the pharmaceutical and medical industries as a diuretic to treat heart and renal diseases, the rising cases of heart and renal diseases, the aging population, fewer side effects, better tolerability, its off-label uses, its wide range of applications, its usage with other diuretics, increasing healthcare awareness among people, cost-efficiency, rising technological advancements, research & development, and regulatory approvals.
Raw Material for Bumetanide Production
According to the Bumetanide production plant project report, the key raw material used in the production of Bumetanide includes 4-chlorobenzoic acid.
Production Process of Bumetanide
The extensive Bumetanide production cost report consists of the following major industrial production process:
- Production from 4-chlorobenzoic acid: The production process of Bumetanide starts with the sulfonylchlorination of 4-chlorobenzoic acid with chlorosulfonic acid to form 4-chloro-3-chlorosulfonylbenzoic acid, which is then nitrated with nitric acid to form an intermediate. The intermediate is treated with ammonia to produce another intermediate, which is then reacted with sodium phenolate to form 5-amino-sulfonyl-3-nitro-5-phenoxybenzoid acid. The nitro group in this compound is reduced by hydrogen using a palladium-on carbon catalyst to give 3-amino-5-aminosulfonyl-5-phenoxybenzoic acid. Finally, this compound is reacted with butyl alcohol in the presence of sulfuric acid to produce Bumetanide.
Bumetanide, commercially known as Bumex, is a crystalline solid having the molecular formula C17H20N2O5S and a molecular weight of 364.4 g/mol. It has a melting point in the range of 230 - 231 °C. It has a water solubility of >20 mg/mL (in base). It has a log P value of 2.6. The value of its dissociation constant, pKa, is 3.83. It dissolves in acetone and alcohol, is soluble to some extent in methylene chloride, and is insoluble in water. Bumetanide is a sulfamyl diuretic that is used to treat nephrotic syndrome, liver and renal disease, and edema associated with congestive heart failure.
